Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics

被引:41
作者
Engel, H [1 ]
Kleespies, C
Friedrich, J
Breidenbach, M
Kallenborn, A
Schöndorf, T
Kolhagen, H
Mallmann, P
机构
[1] Univ Cologne, Dept Obstet & Gynaecol, D-5000 Cologne 41, Germany
[2] Hannover Med Sch, Dept Haematol & Oncol, D-30623 Hannover, Germany
关键词
circulating tumour cells; MACS; FISH;
D O I
10.1038/sj.bjc.6690825
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Detection of micrometastases in patients with solid tumours may aid the establishment of prognosis and development of new therapeutic approaches. This study was designed to investigate the presence and frequency of tumour cells in the peripheral blood (PB) of patients with breast or ovarian cancer by using a combination of magnetic activated cell sorting (MACS) and fluorescence in situ hybridization (FISH). Separated tumour cell and PB-samples from 48 patients (35 breast cancers, 12 ovarian tumours, one uterine sarcoma) were analysed for the presence of numerical aberrations of chromosomes 7, 12, 17 and 17 q11.2-q12. Twenty-five patients had primary disease and 23 had relapsed. The technique allows the detection of one tumour cell in 10(6) normal cells. Circulating tumour cells were detected in 35/48 cases (17 patients had relapsed and 13 primary carcinoma with lymph node or solid metastases) by the expression of anti-cytokeratin and the presence of numerical chromosomal abnormalities. PB-tumour cells of patients with a primary carcinoma and without solid metastases had a significantly lower percentage of chromosomal aberrations, especially for chromosome 12 (P = 0.035; P = 0.038) compared to those with relapsed disease and solid metastases. Detection and quantification of minimal residual disease may monitor the response to cytotoxic or hormonal therapy and may identify women at risk of relapse. (C) 1999 Cancer Research Campaign.
引用
收藏
页码:1165 / 1173
页数:9
相关论文
共 56 条
  • [1] ERBB2 GENE AMPLIFICATION DETECTED BY FLUORESCENT DIFFERENTIAL POLYMERASE CHAIN-REACTION IN PARAFFIN-EMBEDDED BREAST-CARCINOMA TISSUES
    AN, HX
    NIEDERACHER, D
    BECKMANN, MW
    GOHRING, UJ
    SCHARL, A
    PICARD, F
    VANROEYEN, C
    SCHNURCH, HG
    BENDER, HG
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (05) : 291 - 297
  • [2] Berois N, 1997, ANTICANCER RES, V17, P2639
  • [3] Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients
    Bostick, PJ
    Chatterjee, S
    Chi, DD
    Huynh, KT
    Giuliano, AE
    Cote, R
    Hoon, DSB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2632 - 2640
  • [4] COMPARATIVE-STUDY OF INTERPHASE CYTOGENETICS, FLOW CYTOMETRIC ANALYSIS, AND NUCLEAR GRADE OF FINE-NEEDLE ASPIRATES OF BREAST-CARCINOMA
    CAJULIS, RS
    KOTLIAR, S
    HAINES, GK
    FRIASHIDVEGI, D
    OGORMAN, M
    [J]. DIAGNOSTIC CYTOPATHOLOGY, 1994, 11 (02) : 151 - 158
  • [5] Cote RJ, 1996, CANCER, V77, P613, DOI 10.1002/(SICI)1097-0142(19960215)77:4<613::AID-CNCR5>3.0.CO
  • [6] 2-H
  • [7] PREDICTION OF EARLY RELAPSE IN PATIENTS WITH OPERABLE BREAST-CANCER BY DETECTION OF OCCULT BONE-MARROW MICROMETASTASES
    COTE, RJ
    ROSEN, PP
    LESSER, ML
    OLD, LJ
    OSBORNE, MP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) : 1749 - 1756
  • [8] COTE RJ, 1995, ANN SURG, V222, P415
  • [9] SENSITIVE DETECTION OF OCCULT BREAST-CANCER BY THE REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION
    DATTA, YH
    ADAMS, PT
    DROBYSKI, WR
    ETHIER, SP
    TERRY, VH
    ROTH, MS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) : 475 - 482
  • [10] DEVILEE P, 1988, CANCER RES, V48, P5825